GDF15 blockade can reduce immunotherapy resistance in urothelial cancer

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2025-02-11 DOI:10.1038/s41585-025-01005-x

Maria Chiara Masone

引用次数: 0

Abstract

A new study published in Nature reports results from the phase I/IIa study GDFATHER, showing synergistic effects of the neutralizing anti-GDF15 antibody visugromab in combination with the anti-PD1 antibody nivolumab in patients with urothelial cancer.

This trial builds on results in preclinical models showing that GDF15 blockade enhanced the efficacy of PD1-mediated immunotherapy, indicating the potential of anti-GDF15 antibodies in mitigating immunotherapy resistance.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.